medigraphic.com
ISSN 1817-5996 (Electronic)

2013, Number 1

<< Back Next >>

Rev Cub de Reu 2013; 15 (1)

Osteoporosis, falls and hip fractures. Three events with consequences in old people

Delgado MJC, García EA, Vázquez CM, Campbell MM

Language: Spanish
References: 31
Page:
PDF size: 145.19 Kb.


ABSTRACT

Introduction: These events motivated us to conduct this review as this was a concern for the geriatric population and their relatives.
Objectives: To indentify and control risk factors in order to reduce their prevalence.
Method: review of updated bibliography conducted to know about trends worldwide.
Results: re the osteoporosis negatively affecting factors are genetic influence, diet during childhood and adolescence, diet poor in calcium, wrong management of situations with high requirements of calcium like pregnancy and breastfeeding periods, menopause, family history of osteoporosis, early hypoestrogenism, sedentary life style, toxic habits and medicine consumption. Falls can be provoked by intrinsic and extrinsic or environmental causes and most hip fractures are secondary consequences from previous processes, it is assumed that these facture have osteoporotic causes and the current trend shows an increase of these figures as life expectancy also increases in the Cuban population, creating a higher dependence and repercussion in the family dynamics.
Conclusions: due to different reasons there is an increase of these events that have serious consequences in the quality of life of our elder people. Recommendation: to initiate, guide and organize processes that promote educational experiences that have a favorable influence in the knowledge, attitudes and practices of these individuals and their family in relation to their health problems.


REFERENCES

  1. Lluís Pérez Edoa, Alberto Alonso Ruizb, Daniel Roig Vilasecac, Alberto García Vadillod, Nuria Guañabens Gaye, Pilar Perise, et al. Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. Reumatol Clin. 2011; 7(6):357–379.

  2. Adler RA. Glucocorticoid-induced osteoporosis: management update. Curr Osteoporos Rep. 2010; 8:10–4.

  3. Pazianas M, Abrahmsen BO. Safety of bisphosphonate. Bone 2011; 49: 103-10.

  4. Martyn-St James M, Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab. 2010; 28:251–67.

  5. Pérez-Nuñez MI, Riancho del Corral JA. Vertebroplastia y cifoplastia como tratamiento de las fracturas vertebrales osteoporóticas. Rev Osteopor Metab Miner. 2010;2: 27–33.

  6. Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010; 24:75–81.

  7. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95: 5258– 65.

  8. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int. 2010; 21: 1657–80.

  9. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19–26.

  10. Michelson JD, Myers A, Jinnah R, Cox Q, Van Natta M. Epidemiology of hip fractures among the elderly: risk factors for fracture type. Clin Orthop 2005; 311: 129- 35.

  11. Body J-J, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010; 21: 1657-80.

  12. Salica D, Buceta A, Palacios S, Sánchez A, et al. Consenso Iberoamericano de Osteoporosis SIBOMM 2009. Osteoporosis: Prevención, Diagnóstico y Tratamiento. Rev Arg Osteol 2010; 9: 4-44.

  13. Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH, Einhorn TA, Johnston CC, to Raisz LG, Silverman SL, Siris ES. Fractures attributable osteoporosis: report froin the National Osteoporosis Foundation. J Bone Miner Res 2007; 12: 16-23.

  14. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male rats. J Bone Miner Res. 2010; 25: 2647–56.

  15. Beratarrechea A, Diehl M, Saimovici J, Pace N, Trossero A, Plantalech L. Mortalidad a largo plazo y factores predictores en pacientes con fractura de cadera. Actual Osteol 2011; 7: 9-18.

  16. Martinez Saleater A.,Milvaques L .¨Caídas en el Anciano¨ D.E. Clínica Geriátrica El Castillo 2006

  17. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011; 89: 91-104.

  18. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010; 6:325–43.

  19. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary referente intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-8.

  20. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010; 6:82–8.

  21. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25: 948–59.

  22. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362:1761–71.

  23. Rogmark C, Sernbo I, Johnell O, Nilsson JA. Incidence of hip fractures in Malmö, Sweden, 1992-1995.ActaOrthopScand 1999; 70:19-22.

  24. Hansen KH, Wilson HA, Zapalowski C, Fink HA, Minisola S, Adler RA. Uncertainties in the prevention and treatment of glucocorticoid -induced osteoporosis. J Bone Miner Res 2011; 26: 1089-996.

  25. Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010; 21:145–55.

  26. Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV,Marvell T, Monnell TE, et al. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques. Bone. 2010; 46: 64–71.

  27. Adler RA. Glucocorticoid-induced osteoporosis: management update. Curr Osteoporos Rep. 2010; 8:10–4.

  28. Martyn-St James M, Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab. 2010; 28: 251–67.

  29. Albrand G, Muñoz F, Sornay-Rendú E, et al. Independents predictors of all osteoporosis-related fractures in healthy post-menopausal women.TheOfelystudy. Bone 2006; 32(1): 78- 85.

  30. Borges López JA, González ZA, Reyes Llerena Gil A, y cols. Fracturas osteoporóticas fatales por caídas en pacientes de la tercera edad. 1990-1999. Rev Cub Reumatol 2001; III (1): 15-24.

  31. M.Villa Juan ¨La ley de la dependencia ya es una realidad¨ Sesenta y más. Publicación del Ministerio de Trabajo y Asuntos Sociales. IMSERSO. 2006; 255 (7): 17-32.




2020     |     www.medigraphic.com